Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

AD/PD 2023

Browse Popular Uploads...

View all
10:55
Novel combination therapy PrimeC in ALS: biomarker data & launch of Phase II trial
Shiran Salomon-Zimri • 27 Mar 2023
7:08
Long-term follow up of LECIG use in Sweden
Dag Nyholm • 24 Mar 2023
6:10
Latest developments in Parkinson’s disease biomarkers
Andrea Pilotto • 23 Mar 2023
1:30
Cell- and gene-therapy landscape in Parkinson’s disease
Emma Lane • 29 Mar 2023

Parkinson's Disease Treatment... What's on the Horizon?

View all
2:37
Novel brain penetrant capsids for Parkinson’s disease gene therapy
Todd Carter • 29 Mar 2023
2:02
Phase I study of selnoflast to slow neurodegeneration in Parkinson’s disease
Gennaro Pagano • 5 Apr 2023
2:23
Key questions for cell and gene therapy trials in Parkinson’s disease
Emma Lane • 29 Mar 2023
2:34
Ongoing efforts to improve levodopa-based treatments in Parkinson’s disease
Dag Nyholm • 24 Mar 2023

Expert Perspectives

View all
1:17
Highlights of the AD/PD conference 2023
Tiago Outeiro • 25 Apr 2023
1:44
What is the significance of gastrointestinal involvement in Parkinson’s disease?
Dag Nyholm • 24 Mar 2023
2:03
What is the future of immunotherapy in Parkinson’s disease?
Gennaro Pagano • 5 Apr 2023
2:07
Future of tau-targeting immunotherapies in Alzheimer’s disease
Todd Carter • 29 Mar 2023

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJNeurology is intended for healthcare professionals